Use of the Tesio catheter for hemodialysis in patients with end-stage renal failure: a 2-year prospective study

被引:0
|
作者
Webb, A [1 ]
Abdalla, M [1 ]
Harden, PN [1 ]
Russell, GI [1 ]
机构
[1] St Lukes Hosp, Bradford BD5 0NA, W Yorkshire, England
关键词
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The Tesio catheter system has been proposed to be a reliable source of vascular access for the dialysis patient with low rates of infection and other complications. Whether such catheters provide reliable short- and long-term access remains undetermined. Methods: This study prospectively examined all Tesio lines inserted over a 2-year period in patients with end-stage failure with careful recording of all catheter complications and reasons for catheter loss. Results: 100 catheters were inserted in 82 patients giving a total experience of 13,749 catheter days; 74 catheters were inserted into the jugular veins, the remainder into the femoral veins; 82 insertions were covered with antibiotics. At the end of the study, 29 catheters remained in situ. Of the remaining 71 catheters, 27 catheters were removed because of fashioning of definitive access. Nine catheters were lost due to infection and 10 were lost due to non-function; 19 patients died with a functioning catheter. Episodes of non-function were the major complications, although catheter patency was restored in 90% of cases utilizing urokinase and warfarin. Overall 80% of femoral and 16% of jugular catheters required anticoagulation. Conclusions: Tesio catheters inserted into the jugular or femoral veins can provide excellent access whilst awaiting definitive dialysis access. They are well-tolerated with a low complication rate compared to standard temporary central venous catheters. Non-function remains a significant problem, especially in femoral catheters, which should be anticoagulated following insertion. Because of our results we suggest that these catheters be used as part of the co-ordinated approach to the management of vascular access in endstage renal failure patients without definitive access.
引用
收藏
页码:128 / 133
页数:6
相关论文
共 50 条
  • [1] Spironolactone Use in Heart Failure Patients With End-Stage Renal Disease on Hemodialysis: Is It Safe?
    Chua, Doson
    Lo, Anita
    Lo, Chris
    CLINICAL CARDIOLOGY, 2010, 33 (10) : 604 - 608
  • [2] HEMODIALYSIS CLEARANCE OF ETHOSUXIMIDE IN END-STAGE RENAL-FAILURE PATIENTS
    MARBURY, TC
    LEE, CS
    PERCHALSKI, RJ
    WANG, LH
    WILDER, BJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (02) : 264 - 264
  • [3] Atherosclerosis in patients with end-stage renal failure prior to initiation of hemodialysis
    Hojs, R
    Hojs-Fabjan, T
    Balon, BP
    RENAL FAILURE, 2003, 25 (02) : 247 - 254
  • [4] QT dispersion in patients with end-stage renal failure and during hemodialysis
    Lorincz, I
    Mátyus, J
    Zilahi, Z
    Kun, C
    Karányi, Z
    Kakuk, G
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1999, 10 (06): : 1297 - 1302
  • [5] Acne nodulocystica disseminata in Patients with end-stage Renal Failure and Hemodialysis
    Sommer, K.
    Krieter, M.
    Mordstein, V.
    Schultz, E.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 138 - 138
  • [6] Circulating adrenomedullin in patients with end-stage renal failure on hemodialysis.
    Toepfer, MW
    Sitter, T
    Hartmann, G
    Sepp, FB
    Held, E
    Schiffl, H
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A1567 - A1567
  • [7] Complementary use of peritoneal and hemodialysis: Therapeutic synergies in the treatment of end-stage renal failure patients
    Kawanishi, H.
    McIntyre, C.
    KIDNEY INTERNATIONAL, 2008, 73 : S63 - S67
  • [8] 2-Year Natural History of Lower Limbs in Patients With End-stage Renal Disease on Hemodialysis Due to Diabetic Nephropathy; From PREDICT Study
    Kato, Tamon
    Miyashita, Yusuke
    Miura, Takashi
    Ebisawa, Souitirou
    Saigusa, Tatsuya
    Kuwahara, Koichiro
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (18) : B71 - B71
  • [9] REMOVAL OF IMIPENEM AND CILASTATIN BY HEMODIALYSIS IN PATIENTS WITH END-STAGE RENAL-FAILURE
    KONISHI, K
    SUZUKI, H
    SARUTA, T
    HAYASHI, M
    DEGUCHI, N
    TAZAKI, H
    HISAKA, A
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (08) : 1616 - 1620
  • [10] Prognosis of bedridden patients with end-stage renal failure after starting hemodialysis
    Sugaya K.
    Hokama A.
    Hayashi E.
    Naka H.
    Oda M.
    Nishijima S.
    Miyazato M.
    Hokama S.
    Ogawa Y.
    Clinical and Experimental Nephrology, 2007, 11 (2) : 147 - 150